{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.0","value":"-69.0"},{"groupId":"OG001","spread":"56.4","value":"-76.5"},{"groupId":"OG002","spread":"18.9","value":"-89.2"},{"groupId":"OG003","spread":"12.3","value":"-88.6"},{"groupId":"OG004","spread":"11.6","value":"-81.4"},{"groupId":"OG005","spread":"40.7","value":"-63.3"},{"groupId":"OG006","spread":"22.0","value":"-79.3"},{"groupId":"OG007","spread":"57.1","value":"-71.0"},{"groupId":"OG008","spread":"45.7","value":"-80.4"},{"groupId":"OG009","spread":"25.3","value":"-86.0"},{"groupId":"OG010","spread":"4.0","value":"-91.2"},{"groupId":"OG011","spread":"31.5","value":"-71.3"},{"comment":"Could not be calculated for N = 1","groupId":"OG012","spread":"NA","value":"-23.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"81"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"1"}],"units":"Participants"}],"title":"Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"94.7","value":"-54.8"},{"groupId":"OG001","spread":"192.9","value":"-54.5"},{"groupId":"OG002","spread":"63.3","value":"-68.9"},{"groupId":"OG003","spread":"12.5","value":"-89.5"},{"groupId":"OG004","spread":"14.5","value":"-80.7"},{"groupId":"OG005","spread":"18.5","value":"-84.8"},{"groupId":"OG006","spread":"61.8","value":"-70.6"},{"groupId":"OG007","spread":"94.7","value":"-65.6"},{"groupId":"OG008","spread":"224.0","value":"-47.2"},{"groupId":"OG009","spread":"422.0","value":"-35.6"},{"groupId":"OG010","spread":"8.0","value":"-89.8"},{"groupId":"OG011","spread":"83.8","value":"-60.6"},{"groupId":"OG012","spread":"120.5","value":"-53.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"102"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"3"}],"units":"Participants"}],"title":"Cycle 2, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"102"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"12"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"3"}],"units":"Participants"}],"description":"Plasma 2-HG was measured using qualified LC-MS/MS, the LLOQ was 30.0 ng/mL. Minimum percent change from Baseline response value post-dose over 10 hours was calculated as: (minimum observed concentration post-dose over 10 hours \\[Rmin\\] - Baseline) / Baseline \\* 100. Baseline was equal to the average of the Screening and Day -3 (predose) 2-HG values. Data reported are the arithmetic mean and relative standard deviation expressed as a percentage.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received enasidenib 30 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Enasidenib 30 mg BID"},{"description":"Participants received enasidenib 50 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG001","title":"Enasidenib 50 mg BID"},{"description":"Participants received enasidenib 75 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG002","title":"Enasidenib 75 mg BID"},{"description":"Participants received enasidenib 100 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity","id":"OG003","title":"Enasidenib 100 mg BID"},{"description":"Participants received enasidenib 150 mg tablets BID on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG004","title":"Enasidenib 150 mg BID"},{"description":"Participants received enasidenib 50 mg tablets every day (QD) on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG005","title":"Enasidenib 50 mg QD"},{"description":"Participants received enasidenib 75 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG006","title":"Phase 1 Dose Escalation: Enasidenib 75 mg QD"},{"description":"Participants received enasidenib 100 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG007","title":"Phase 1 Dose Escalation: Enasidenib 100 mg QD"},{"description":"Participants received enasidenib 150 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG008","title":"Phase 1 Dose Escalation: Enasidenib 150 mg QD"},{"description":"Participants received enasidenib 200 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG009","title":"Phase 1 Dose Escalation: Enasidenib 200 mg QD"},{"description":"Participants received enasidenib 300 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG010","title":"Phase 1 Dose Escalation: Enasidenib 300 mg QD"},{"description":"Participants received enasidenib 450 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG011","title":"Phase 1 Dose Escalation: Enasidenib 450 mg QD"},{"description":"Participants received enasidenib 650 mg tablets QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG012","title":"Phase 1 Dose Escalation: Enasidenib 650 mg QD"}],"paramType":"MEAN","populationDescription":"Participants who received enasidenib on Cycle 2, Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis. Participants in the Phase 1 Escalation and Expansion Enasidenib 100 mg QD cohorts were combined for analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Day 15 and Cycle 2, Day 1 at predose and 0.5, 1, 2, 3, 4, 6, 8, and 10 hours post-dose.","title":"Phase 1: Minimum Percent Change From Baseline Response Value Post-dose Over 10 Hours (%BRmin) for 2-HG After Multiple Oral Doses of Enasidenib","type":"SECONDARY","unitOfMeasure":"percent change"}